Sepsis – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23034IDB-L5

Select Item

Empower your strategies with our Sepsis – Drugs In Development, 2024 report and make more profitable business decisions.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function, and abdominal pain. The predisposing factors include age and weakened immune system. Treatment includes antibiotics and vasopressors.

The Sepsis drugs in development market research report provide comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Sepsis
Key Targets
· Lipopolysaccharide ; Toll Like Receptor 4; Tumor Necrosis Factor; Toll Like Receptor 2; Monocyte Differentiation Antigen CD14; Peptidoglycan; Proadrenomedullin; NACHT LRR And PYD Domains Containing Protein 3; Adenosine Receptor A2a; and Adenosine Receptor A2b
Key Mechanisms of Action
· Lipopolysaccharide Inhibitor; Toll Like Receptor 4 Antagonist; Tumor Necrosis Factor Inhibitor; Toll Like Receptor 2 Antagonist; NACHT LRR And PYD Domains Containing Protein 3 Inhibitor; Monocyte Differentiation Antigen CD14 Inhibitor; Peptidoglycan Inhibitor; Adenosine Receptor A2b Agonist; and Adenosine Receptor A2a Antagonist
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Intramuscular; Parenteral; Topical; Inhalational; Intravenous Drip; Ophthalmic; and Nasal
Key Molecule Types
· Small Molecule; Synthetic Peptide; Recombinant Protein; Monoclonal Antibody; Conjugate Vaccine; Peptide; Cell Therapy; Biologic; Fusion Protein; and Protein
Major Companies
· Purine Pharmaceuticals Inc; University of Seville; The Feinstein Institute for Medical Research; TheraSource LLC; Syntiron LLC; Signablok Inc; Vascular BioSciences; Oryn Therapeutics; Grand Pharmaceutical Group Ltd; and Jiangsu Kunli Biopharmaceutical Co Ltd

Scope

  • Therapeutics in Development: Covering 171 molecules, with 145 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Sepsis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Sepsis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sepsis treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

A2 Therapeutics Inc
A6 Pharmaceuticals LLC
ABIONYX Pharma SA
AbVacc Inc
Acepre LLC
ADEL Inc
Adrenomed AG
AiCuris Anti-infective Cures AG
AIM Vaccine Co Ltd
Aldeyra Therapeutics Inc
Allele Biotechnology and Pharmaceuticals Inc
Alphamab Oncology
Annexin Pharmaceuticals AB
Apoglyx AB
Aptahem AB
Arch Biopartners Inc
Asahi Kasei Pharma Corp
Axceso Biopharma Co Ltd
Ayuvis Research Inc
Basilea Pharmaceutica Ltd
BioAegis Therapeutics Inc
BloodCenter of Wisconsin
Brandenburg Antiinfektiva GmbH
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellics Therapeutics Inc
Cellivery Therapeutics Inc
Celloram Inc
Centers of Biomedical Research Network
Chengdu Olymvax Biopharmaceuticals Inc
Children's Hospital of Philadelphia
Chongqing Zhifei Biological Products Co Ltd
Cilian AG
Claritas Pharmaceuticals Inc
Covira Surgical Inc
Cynata Therapeutics Ltd
Deka Biosciences Inc
Dupage Medical Technology Inc
Dynomics Inc
Eight Plus One Pharmaceutical Co Ltd
Eldec Pharmaceuticals Inc
Endacea Inc
Enlivex Therapeutics Ltd
Enzychem Lifesciences Corp
Eunoia Biotech LLC
Evaxion Biotech A/S
Exoxemis Inc
Fe Pharmaceuticals Inc
Function Therapeutics Inc
Genesen Co Ltd
Genfit SA
Grand Pharmaceutical (China) Co Ltd
Grand Pharmaceutical Group Ltd
Grifols SA
Gufic BioSciences Ltd
Hibernaid Inc
HLB Science Inc
Hunan Sanqing Pharmaceutical Co Ltd
Ibex Bioscience Inc
ILIAS Biologics Inc
InflaRx NV
Issar Pharmaceuticals Pvt Ltd
JD Bioscience Inc
Jiangsu Kunli Biopharmaceutical Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
KARE Biosciences Inc
Karl-Franzens-Universitat Graz
Korea Research Institute of Bioscience and Biotechnology
Lead Discovery Center GmbH
LEAF4Life LLC
LifeArc
Marshall University
Matisse Pharmaceuticals BV
MedAbome Inc
Medical University of South Carolina
MetrioPharm AG
Microbiotix Inc
MirimGENE Co Ltd
Mochida Pharmaceutical Co Ltd
Modus Therapeutics AB
MYND Life Sciences Inc
Nanotics LLC
Northern Therapeutics Inc
Nosopharm SAS
NovaCell Technology Inc
Novartis AG
Ohio State University
Ono Pharmaceutical Co Ltd
Orbsen Therapeutics Ltd
Oryn Therapeutics
Osaka University
Paean Biotechnology Inc
Panag Pharma Inc
ProAbTech Ltd
ProThera Biologics Inc
Protheragen Inc
Purine Pharmaceuticals Inc
Pylum Biosciences Inc
Q BioMed Inc
Qrons Inc
Ra Pharmaceuticals Inc
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
Revagenix Inc
Reven Holdings Inc
RevImmune SAS
Rimonyx Pharmaceuticals Ltd
Sanofi
SATT AxLR SAS
SciClone Pharmaceuticals Holdings Ltd
Scioto Biosciences Inc
SelectImmune Pharma AB
Sentien Biotechnologies Inc
Seoul National University
SetLance srl
SFA Therapeutics Inc
Shaperon Inc
Shionogi & Co Ltd
Signablok Inc
SignPath Pharma Inc
Sorbonne University
Sulfateq BV
Summit Therapeutics Inc
Suzhou Weichao Biotechnology Co Ltd
Swedish Orphan Biovitrum AB
Synthekine Inc
Syntiron LLC
TaiRx Inc
Techfields Pharma Co Ltd
The Feinstein Institute for Medical Research
Therakind Ltd
Therapeutic Systems Research Laboratories Inc
TheraSource LLC
Tianjin Chase Sun Pharmaceutical Co Ltd
UAB Minority Health and Health Equity Research Center
University of California Riverside
University of Louisville
University of Malaya
University of Seville
US Army Medical Research & Materiel Command
ValiRx Plc
Vascular BioSciences
Weizmann Institute of Science
Wenzhou Medical University
West Lake Biomedical Technology (Hangzhou) Co Ltd
Worphmed Srl
Yabao Pharmaceutical Group Co Ltd
YNIOS Pharma srl
Zhejiang University
Zydus Lifesciences Ltd
ZZ Biotech LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Sepsis reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Sepsis – Drugs In Development, 2024 in real time.

  • Access a live Sepsis – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more